Nephrocare Health IPO Details
The Nephrocare Health IPO is a book build issue with a total issue size of ₹871.05 cr, comprising of fresh issue of 7682717 equity shares., and a offer for sale of 11253102 equity shares. Nephrocare Health IPO opened for subscription on Dec 10, 2025 and closed on Dec 12, 2025. Nephrocare Health IPO is set price band at ₹438 to ₹460 per share, with a lot size of 32 shares. Minimum investment for Retail investors was ₹14,720.00 (at the upper price band) to apply for one lot.
The basis of allotment got finalized on Dec 15, 2025, and listed on both the NSE and BSE on Dec 17, 2025.
Kfin Technologies Limited has been appointed as the registrar. Ambit Private Limited, IIFL Capital Services Limited, ICICI Securities Limited and Nomura Financial Advisory And Securities (India) Pvt Ltd are the Book Running Lead Manager for the issue.
Before investing in the Nephrocare Health IPO, investors should review the company's financial performance, business objectives, and risk factors mentioned in the offer documents and apply before the subscription window closes.
- Price Band
- ₹ 438 – 460
- Lot Size
- 32
- Issue Size
- ₹871.05 Cr
- Minimum Investment
- ₹14720 (32 Shares)
- Listing Date
- 17 December 2025
Current GMP
₹40 (+8.70%)
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
About Nephrocare Health Services Limited
Nephrocare Health Services Ltd., incorporated in 2010, is a leading provider of end-to-end dialysis care, operating a wide network of clinics across India and select international markets. Its comprehensive service portfolio includes diagnosis, haemodialysis, home and mobile dialysis solutions, wellness programs, and support from an in-house pharmacy.
As of September 30, 2025, Nephrocare operated 519 clinics, including 51 centers in the Philippines, Uzbekistan, and Nepal. Notably, the network features the world’s largest dialysis clinic in Uzbekistan. Within India, the company is present in 288 cities across 21 States and 4 Union Territories, with 77.53% of its clinics located in tier-II and tier-III cities—significantly improving access to dialysis care in underserved regions.
During Fiscal 2025, Nephrocare served 29,281 patients and completed 2,885,450 dialysis treatments, representing approximately 10% of India’s total dialysis patient base. By September 30, 2025, the company had already served 31,046 patients and completed 1,591,377 treatments in India alone. Its operations are supported by a fleet of 5,562 dialysis machines as of the same date.
Nephrocare has also established strategic collaborations with several major hospital chains to operate in-house dialysis centers. Key partners include Max Super Speciality Hospital, Fortis Escorts Hospitals, CARE Hospitals, Wockhardt Hospitals, Paras Healthcare, The Calcutta Medical Research Institute, Jehangir Hospital, and Ruby Hall Clinic.
Nephrocare Health IPO Promoters
- Vikram Vuppala
- Bessemer Venture Partners Trust
- Edoras Investment Holdings Pte. Ltd
- Healthcare Parent Limited
- Investcorp Private Equity Fund II
- Investcorp Growth Opportunity Fund
Promoters Holding
Holding Pre Issue
78.90%
Holding Post Issue
0.00%
Nephrocare Health IPO Objective
The Company Nephrocare Health IPO proposes to utilise the Net Proceeds from the Issue towards the following objects.
- Capital expenditure by the Company for opening new dialysis clinics in India and
- Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by the Company
- General corporate purposes
Address / Contact Info
Nephrocare Health Services Ltd.
5 th Floor, D Block, iLabs Centre,
Plot 18, Software Units Layout,
Survey No. 64, Madhapur, Shaikpet,
Hyderabad, Telangana, 500081
Phone: +91 40 4240 8039
Email: cs@nephroplus.com
Website: http://www.nephroplus.com/
IPO Snapshot
Book Running Lead Managers
- Ambit Private Limited
- IIFL Capital Services Limited
- ICICI Securities Limited
- Nomura Financial Advisory And Securities (India) Pvt Ltd
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
Nephrocare Health IPO is a Book-building IPO with a total issue size of ₹871.05 crore. The Nephrocare Health IPO price band is ₹438 to 460 per share. The Nephrocare Health IPO subscription opens on Wed, Dec 10, 2025, and closes on Fri, Dec 12, 2025. The Nephrocare Health IPO will be listed on the BSE,NSE. Kfin Technologies Limited is the registrar for the Nephrocare Health IPO.
The Nephrocare Health IPO opens on Wed, Dec 10, 2025 and closes on Fri, Dec 12, 2025
Nephrocare Health IPO Price Band is ₹438 to 460 per share.
Nephrocare Health IPO lot size is 32 shares, Retail investors need a minimum investment of ₹14720 based on the upper price band
The minimum investment for Nephrocare Health IPO is ₹14720, based on one lot of 32 shares at the upper price band of ₹460 per share.
Investors can apply for the Nephrocare Health IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Fri, Dec 12, 2025. The application amount remains blocked until the Nephrocare Health IPO allotment is finalized.
Nephrocare Health IPO issue size is ₹871.05 crores.
Nephrocare Health IPO allotment date is Wed, Jul 1, 2026.
The registrar for Nephrocare Health IPO is Kfin Technologies Limited. Investors can go to Kfin Technologies Limited website to check Nephrocare Health IPO allotment status, refund processing, and other IPO-related information.
The Nephrocare Health IPO GMP (Grey Market Premium) is ₹40 as of Wed, Dec 17, 2025. Based on the upper price band of ₹460 per share, the estimated Nephrocare Health IPO listing price is ₹500, indicating a potential listing gain of approximately 0% over the issue price.